The answer depends on the exact pathway
There is no responsible one-word answer to “Is stem cell therapy legal in China?” China has multiple routes for biomedical technologies, including drug and medical-device development, registered clinical research and approved clinical translation or application under defined conditions. The exact product, indication, institution and route must be identified.
A hospital may conduct research without being able to sell the intervention as routine treatment. A company may be developing a cell product through formal clinical trials. A specific institution may also operate a clinical-translation project under an authorised framework. These situations are different.
China’s 2026 biomedical-technology framework
China’s Regulation on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical Technologies took effect on 1 May 2026. It creates a framework for clinical research and for moving eligible technologies toward clinical application.
Important patient principle
Clinical research and paid clinical application are not the same. Research institutions must not charge participants fees related to the biomedical-new-technology study. A provider should therefore explain whether the patient is entering research, an approved clinical application or another regulated product pathway.
What “approved” should mean in a patient conversation
The word “approved” is often used too broadly. Patients should ask: approved by whom, for which institution, for which indication, under which route, and whether the approval is current?
| Claim | What to verify |
|---|---|
| “Government approved” | Official decision, exact technology, institution and indication |
| “Clinical trial registered” | Registry number, recruitment status, site and protocol |
| “Hospital research project” | Whether it is research only or a patient-access pathway |
| “Available in Hainan/China” | Current foreign-patient intake and institutional instructions |
Foreign-patient access is a separate question
A domestic pathway may exist while foreign-patient intake is unavailable, paused or subject to different documents and follow-up requirements. International access should be confirmed directly by the hospital, including passport eligibility, remote review, language support, payment, travel time and follow-up.
How Regenerative Medicine China labels status
We use four primary public labels: International Access Confirmed, International Access Pending, Registered Clinical Trial and Research Only. We do not upgrade a pathway to confirmed access merely because a news article, company announcement or competitor website says treatment exists.
Sources patients can use
Useful source categories include official government or regulator pages, the treating hospital, recognised clinical-trial registries, peer-reviewed literature and independent patient-safety guidance from organisations such as the ISSCR. Commercial websites may provide leads, but they should not be the sole proof of approval or efficacy.